Fine-mapping of SNCA in REM sleep behavior disorder and overt synucleinopathies

Objective REM-sleep behavior disorder (RBD) is a prodromal synucleinopathy, as >80% will eventually convert to overt synucleinopathy. We performed an in-depth analysis of the SNCA locus to identify RBD-specific risk variants. Methods Full sequencing and genotyping of SNCA was performed in isolated/idiopathic RBD (iRBD, n=1,076), Parkinson’s disease (PD, n=1,013), and dementia with Lewy bodies (DLB, n=415), and in control subjects (n=6,155). A replication cohort from 23andMe of PD patients with probable RBD (pRBD) was also analyzed (cases n=1,782, controls n=131,250). Adjusted logistic regression models and meta-analyses were performed. Effects on conversion rate were analyzed in 432 RBD patients with available data using Kaplan-Meier survival analysis. Results A 5’-region SNCA variant (rs10005233) was associated with iRBD (OR=1.43, p=1.1E-08), which was replicated in pRBD. This variant is in linkage disequilibrium (LD) with other 5’ risk variants across the different synucleinopathies. An independent iRBD-specific suggestive association (rs11732740) was detected at the 3’ of SNCA (OR=1.32, p=4.7E-04, not statistically significant after Bonferroni correction). Homozygous carriers of both iRBD-specific SNPs were at highly increased risk for iRBD (OR=5.74, p=2E-06). The known top PD-associated variant (3’ variant rs356182) had an opposite direction of effect in iRBD compared to PD. Interpretation There is a distinct pattern of association at the SNCA locus in RBD as compared to PD, with an opposite direction of effect at the 3’ of SNCA. Several 5’ SNCA variants are associated with iRBD and with pRBD in overt synucleinopathies, and may suggest a cognitive component to this region.

[1]  Dawn M. Toolan,et al.  Functionalization of the TMEM175 p.M393T variant as a risk factor for Parkinson disease , 2019, Human molecular genetics.

[2]  W. Rowell,et al.  The landscape of SNCA transcripts across synucleinopathies: New insights from long reads sequencing analysis , 2019, bioRxiv.

[3]  Yves Dauvilliers,et al.  REM sleep behaviour disorder , 2018, Nature Reviews Disease Primers.

[4]  Sonja W. Scholz,et al.  Parkinson’s disease genetics: identifying novel risk loci, providing causal insights and improving estimates of heritable risk , 2018, bioRxiv.

[5]  W. Oertel,et al.  LRRK2 protective haplotype and full sequencing study in REM sleep behavior disorder. , 2018, Parkinsonism & related disorders.

[6]  M. Nalls,et al.  A comprehensive analysis of SNCA‐related genetic risk in sporadic parkinson disease , 2018, Annals of neurology.

[7]  A. Desautels,et al.  Full sequencing and haplotype analysis of MAPT in Parkinson's disease and rapid eye movement sleep behavior disorder , 2018, Movement disorders : official journal of the Movement Disorder Society.

[8]  E. Dietrichs,et al.  Risk variants of the α-synuclein locus and REM sleep behavior disorder in Parkinson’s disease: a genetic association study , 2018, BMC Neurology.

[9]  Birgit Frauscher,et al.  Prevalence and determinants of rapid eye movement sleep behavior disorder in the general population , 2018, Sleep.

[10]  Sonja W. Scholz,et al.  Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study , 2018, The Lancet Neurology.

[11]  J. Santamaria,et al.  Idiopathic REM sleep behavior disorder in the elderly Spanish community: a primary care center study with a two-stage design using video-polysomnography. , 2017, Sleep medicine.

[12]  M. Nalls,et al.  A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci , 2017, Nature Genetics.

[13]  A. Desautels,et al.  The dementia-associated APOE ε4 allele is not associated with rapid eye movement sleep behavior disorder , 2017, Neurobiology of Aging.

[14]  Daniela Berg,et al.  Advances in markers of prodromal Parkinson disease , 2016, Nature Reviews Neurology.

[15]  Sonja W. Scholz,et al.  A genome-wide association study in multiple system atrophy , 2016, Neurology.

[16]  Y. Dauvilliers,et al.  Analysis of DNAJC13 mutations in French-Canadian/French cohort of Parkinson's disease , 2016, Neurobiology of Aging.

[17]  Ekaterina Nosova,et al.  α‐synuclein genetic variability: A biomarker for dementia in Parkinson disease , 2016, Annals of neurology.

[18]  Yonatan Stelzer,et al.  Parkinson-associated risk variant in enhancer element produces subtle effect on target gene expression , 2016, Nature.

[19]  Joan Santamaria,et al.  Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions , 2016, The Lancet Neurology.

[20]  E. Tolosa,et al.  Absence of LRRK2 mutations in a cohort of patients with idiopathic REM sleep behavior disorder , 2016, Neurology.

[21]  Michelle K. Lupton,et al.  Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases , 2016, Neurobiology of Aging.

[22]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[23]  A. Roses,et al.  A cytosine-thymine (CT)-rich haplotype in intron 4 of SNCA confers risk for Lewy body pathology in Alzheimer's disease and affects SNCA expression , 2015, Alzheimer's & Dementia.

[24]  G. Deuschl,et al.  MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[25]  Jean-François Gagnon,et al.  New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression: A Prospective Cohort Comparison With Other Phenotypes. , 2015, JAMA neurology.

[26]  A. Desautels,et al.  GBA mutations are associated with Rapid Eye Movement Sleep Behavior Disorder , 2015, Annals of clinical and translational neurology.

[27]  G. Halliday,et al.  Alpha-synuclein biology in Lewy body diseases , 2014, Alzheimer's Research & Therapy.

[28]  A. Roses,et al.  The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease. , 2014, Human molecular genetics.

[29]  Chuong B. Do,et al.  Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.

[30]  Catherine Boileau,et al.  Cohort profile of the CARTaGENE study: Quebec's population-based biobank for public health and personalized genomics. , 2013, International journal of epidemiology.

[31]  Carlos H Schenck,et al.  Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. , 2013, Sleep medicine.

[32]  T. Kim,et al.  REM sleep behavior disorder in the Korean elderly population: prevalence and clinical characteristics. , 2013, Sleep.

[33]  J. Molinuevo,et al.  Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study , 2013, The Lancet Neurology.

[34]  Xihong Lin,et al.  Optimal tests for rare variant effects in sequencing association studies. , 2012, Biostatistics.

[35]  Poul Jennum,et al.  A single‐question screen for rapid eye movement sleep behavior disorder: A multicenter validation study , 2012, Movement disorders : official journal of the Movement Disorder Society.

[36]  R. Postuma,et al.  Rapid eye movement sleep behavior disorder and risk of dementia in Parkinson's disease: A prospective study , 2012, Movement disorders : official journal of the Movement Disorder Society.

[37]  Chuong B. Do,et al.  Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database , 2012, PLoS genetics.

[38]  A. Singleton,et al.  The Parkinson Progression Marker Initiative (PPMI) , 2011, Progress in Neurobiology.

[39]  Yuichi Inoue,et al.  Utility of the REM sleep behavior disorder screening questionnaire (RBDSQ) in Parkinson's disease patients. , 2011, Sleep medicine.

[40]  Witold R. Rudnicki,et al.  Feature Selection with the Boruta Package , 2010 .

[41]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[42]  Wolfgang Viechtbauer,et al.  Conducting Meta-Analyses in R with the metafor Package , 2010 .

[43]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[44]  K. Marder,et al.  Association of glucocerebrosidase mutations with dementia with lewy bodies. , 2009, Archives of neurology.

[45]  M. Vendette,et al.  Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder , 2009, Neurology.

[46]  Nir Giladi,et al.  Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset , 2008, Neurology.

[47]  J. Doyon,et al.  REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia , 2007, Neurology.

[48]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[49]  D J Brooks,et al.  DLB and PDD boundary issues , 2007, Neurology.

[50]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[51]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[52]  M. Thorpy.  Classification of Sleep Disorders , 1990, Neurotherapeutics.

[53]  Ambra Stefani,et al.  Idiopathic REM sleep behaviour disorder and neurodegeneration — an update , 2018, Nature Reviews Neurology.

[54]  D. Clayton,et al.  A unified stepwise regression procedure for evaluating the relative effects of polymorphisms within a gene using case/control or family data: application to HLA in type 1 diabetes. , 2002, American journal of human genetics.